Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.45 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097984 | 0.86 | MMP13 (0.55) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6095113 | 0.81 | MMP13 (0.51) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6690842 | 0.74 | FPR2 (0.58) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6098585 | 0.74 | FPR2 (0.64) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6094119 | 0.73 | MMP13 (0.57) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6397014 | 0.71 | MMP13 (0.53) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL6518095 | 0.71 | TSHR (0.59) | EPHX2LIPEMAPTSMN1; SMN2 | |
| SCHEMBL6097817 | 0.70 | EPHX2 (0.56) | MMP13MMP2FPR2PROKR1EPHX2 | |
| SCHEMBL6094760 | 0.69 | MMP13 (0.49) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL2089684 | 0.69 | EPHX2 (0.60) | MMP13MMP2FPR2PROKR1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | MMP14, MMP12, MMP17 | MMP13 23/4885MMP2 8/4885FPR2 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.